PrimeC is now FDA-cleared to enter Phase III development in ALS, as competition in the indication intensifies with several ...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing ...

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic ...

The MarketWatch News Department was not involved in the creation of this content. -- 2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS -- ...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disea ...

View Neurosense Therapeutics Ltd. NRSN stock quote prices, financial information, real-time forecasts, and company news from CNN.

CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe ...

Alon Ben-Noon, co-founder and CEO of NeuroSense Therapeutics With the FDA expected to decide in September on Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) treatment known as AMX0035, ...

Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

Shares of clinical-stage biotech company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) are ripping higher Thursday morning after the company reported positive final results from its Alzheimer's biomarker ...

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense ...